Mode
Text Size
Log in / Sign up
N/A N=67 Randomized Treatment

A Study of a Novel Silicone Dressing to Minimize Scar Formation

Hypertrophic

Enrolled (actual)
67
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcome: Primary: Visual Analogue Scale (VAS) — 2.90; 3.29 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
embrace device (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Neodyne Biosciences, Inc.
Primary completion
Sep 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Visual Analogue Scale (VAS)
3.18; 3.85
PRIMARY
Visual Analogue Scale (VAS)
3.18; 3.85
SECONDARY
Patient and Observer Scar Assessment Scale (POSAS) - Patient Results
1.00; 1.06; 1.40; 1.29; 3.80; 4.31
SECONDARY
Patient and Observer Scar Assessment Scale (POSAS) - Patient Results
1.00; 1.06; 1.40; 1.29; 3.80; 4.31
SECONDARY
Patient and Observer Scar Assessment Scale (POSAS) - Observer Results
1.67; 2.25; 1.61; 2.69; 3.36; 3.50
SECONDARY
Patient and Observer Scar Assessment Scale (POSAS) - Observer Results
1.67; 2.25; 1.61; 2.69; 3.36; 3.50
SECONDARY
Patient Satisfaction - Scar Minimization
14; 11; 10; 0; 0
SECONDARY
Patient Satisfaction - Recommend
15; 11; 5; 2; 2
SECONDARY
Patient Satisfaction - Use Again
15; 12; 3; 3; 2
SECONDARY
Patient Satisfaction - Scar Minimization
14; 11; 10; 0; 0
SECONDARY
Patient Satisfaction - Recommend
15; 11; 5; 2; 2
SECONDARY
Patient Satisfaction - Use Again
15; 12; 3; 3; 2

Summary

Neodyne has developed an investigational dressing for post-operative incision care. Neodyne is conducting this research to study whether the investigational dressing, called the Neodyne Dressing, can minimize scar formation in a simple manner.

Eligibility Criteria

Inclusion Criteria

  • Subjects who have undergone a de novo abdominoplasty.
  • Appearance of subject's incision is aesthetically similar across length of incision.

Exclusion Criteria

  • Subjects with a history of collagen vascular disease, cutis laxica, connective tissue disease, psoriasis, or lupus.
  • Subjects diagnosed with scleroderma.
  • Subjects with known adverse reactions to steri-strip tapes, medical tapes, or adhesives.
  • Subjects with oozing, dehiscence, non-closed/healed incisions at time of first application.
  • Subjects with inability to maintain adequate care of incision.
  • Subjects with a body mass index (BMI) > 30.
  • Subjects with a weight loss of greater than or equal to 100 lbs within 6 months from date of abdominoplasty.
  • Subjects who currently smoke.
  • Subjects taking steroid therapy.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01399099). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search